300558.SZ SHZ
Betta Pharmaceuticals Co., Ltd.
1W: -0.5%
1M: +0.0%
3M: -24.9%
YTD: +5.6%
1Y: -25.1%
3Y: +0.2%
5Y: -50.6%
¥50.48 ($7.53)
+1.52 (+3.10%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$2.9B
+17.7% ▲
5Y CAGR: +13.2%
Gross Profit
$2.4B
+14.7% ▲
5Y CAGR: +10.2%
Operating Income
$400M
+48.1% ▲
5Y CAGR: +8.4%
Net Income
$403M
+15.7% ▲
5Y CAGR: +11.8%
EPS (Diluted)
$0.96
+15.7% ▲
5Y CAGR: +11.0%
EBITDA
$845M
+46.2% ▲
5Y CAGR: +13.2%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.9B | $2.2B | $2.4B | $2.5B | $2.9B |
| YoY Growth | +20.4% | +20.1% | +5.8% | +3.3% | +17.7% |
| Cost of Revenue | $139M | $174M | $269M | $404M | $539M |
| Gross Profit | $1.7B | $2.1B | $2.1B | $2.1B | $2.4B |
| Gross Margin | 92.6% | 92.2% | 88.7% | 83.5% | 81.4% |
| R&D Expenses | $363M | $566M | $700M | $640M | $502M |
| SG&A Expenses | $947M | $1.1B | $1.2B | $1.1B | $1.4B |
| Operating Expenses | $1.1B | $1.7B | $2.0B | $1.8B | $2.0B |
| Operating Income | $681M | $396M | $95M | $270M | $400M |
| Operating Margin | 36.4% | 17.6% | 4.0% | 11.0% | 13.8% |
| Interest Expense | $40M | $16M | $196M | $55M | $47M |
| Income Before Tax | $667M | $390M | $88M | $322M | $394M |
| Tax Expense | $66M | $10M | -$37M | -$12M | $7M |
| Net Income | $606M | $383M | $145M | $348M | $403M |
| Net Margin | 32.4% | 17.1% | 6.1% | 14.2% | 13.9% |
| EPS (Diluted) | $1.49 | $0.92 | $0.35 | $0.83 | $0.96 |
| EBITDA | $570M | $518M | $454M | $578M | $845M |
| Shares Outstanding | 407M | 415M | 415M | 419M | 419M |